AstraZeneca targets $80 billion in total revenue by 2030 in 'post-Covid era'
Publishing timestamp: 2024-05-21 04:41:56
Summary
AstraZeneca plans to increase its total revenue to $80 billion by 2030, focusing on oncology, biopharmaceuticals, and rare diseases businesses. The company expects to release 20 new medicines with the potential to be $5 billion drugs. AstraZeneca also announced plans for new manufacturing facilities and acquisitions in the pharmaceutical industry.
Sentiment: POSITIVE
Tickers: AZN-GB, FUSN, NOVO.B-DK, NVO, LLY, AZN,
Keywords: health, health care industry, eli lilly and co, astrazeneca plc, amgen inc, pfizer inc, daiichi sankyo co ltd, business news, business, novo nordisk a/s,
Source: https://www.cnbc.com/2024/05/21/astrazeneca-to-boost-revenue-release-new-medicines-by-2030.html